

# Bi-level Positive Airway Pressure Devices (BiPAP) Market - 2024-2033

<https://marketpublishers.com/r/B3F6C4A84900EN.html>

Date: February 2026

Pages: 186

Price: US\$ 2,999.00 (Single User License)

ID: B3F6C4A84900EN

## Abstracts

The Bi-level Positive Airway Pressure Devices (BiPAP) Market was valued at US\$ 1.45 Billion in 2024 and is anticipated to reach US\$ 3.70 Billion by 2033, at a CAGR of 0.055 from 2026 to 2032.

The report delivers in-depth insights into key market dynamics, including regional growth trends, market segmentation, CAGR projections, and the revenue performance of leading industry players. It also highlights major growth drivers shaping the market landscape. Designed to provide a clear and comprehensive perspective, the report offers a detailed view of the current market size in terms of both value and volume, along with emerging opportunities and the overall development outlook of the Bi-level Positive Airway Pressure Devices (BiPAP) Market.

This report delivers a comprehensive overview of the Bi-level Positive Airway Pressure Devices (BiPAP) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bi-level Positive Airway Pressure Devices (BiPAP) Market. The Bi-level Positive Airway Pressure Devices (BiPAP) Market size, estimates, and forecasts are provided in terms of output/shipments (K MT) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

Bi-level Positive Airway Pressure Devices (BiPAP) Market Scope:

By Product

Devices

Masks

Aftermarket Parts and Accessories

### By Indication

Obstructive Sleep Apnea

Central Sleep Apnea

Complex Sleep Apnea

Chronic Obstructive Pulmonary Disease (COPD)

Acute Respiratory Failure

Chronic Respiratory Failure

Neuromuscular Disorders

Obesity Hypoventilation Syndrome

Pneumonia and Other Respiratory Infections

Post-operative Respiratory Support

Others

### By Technology

Integrated Humidification

Heated Tubing

Smart Connectivity

Bluetooth-enabled Devices

Wi-Fi-enabled Devices

Cloud-based Monitoring

Telemonitoring Compatible Devices

Noise Reduction Technology

Pressure Relief Technology

Leak Compensation Systems

Touchscreen / Digital Interface

Others

#### By Portability

Stationary Devices

Portable Devices

Travel-friendly Devices

Others

#### By Patient Type

Adult

Pediatric

Geriatric

## By End-User

Hospitals

Academic / Teaching Hospitals

Sleep Clinics and Sleep Laboratories

Home Healthcare Settings

Ambulatory Surgical Centers

Long-term Care Facilities

Rehabilitation Centers

Others

## Key Players

Pfizer, Inc.

Otsuka Pharmaceutical Co., Ltd.

GlaxoSmithKline plc

H. Lundbeck A/S

Johnson & Johnson

Bristol-Myers Squibb Company

BioXcel Therapeutics, Inc.

Impel Pharmaceuticals Inc.

Lee Pharma Limited

Teva Pharmaceutical Industries Ltd.

Anneal Pharmaceuticals LLC

AbbVie Inc.

Aurobindo Pharma Limited

Apotex Inc.

F. Hoffmann-La Roche Ltd.

Hikma Pharmaceuticals PLC

Axsome Therapeutics, Inc.

Alkermes plc

Alexza Pharmaceuticals, Inc.

## Major Highlights

This report delivers a comprehensive overview of the Bi-level Positive Airway Pressure Devices (BiPAP) Market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding Bi-level Positive Airway Pressure Devices (BiPAP) Market. The Bi-level Positive Airway Pressure Devices (BiPAP) Market size, estimates, and forecasts are provided in terms of output/shipments (K Sqm) and revenue (US\$ millions), with 2025 as the base year and historical and forecast data for 2024–2033.

This report will assist keyword manufacturers, new entrants, and companies across the industry value chain with information on revenues, production, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

## Regional Analysis:

North America (U.S., Canada, Mexico)

Europe (U.K., Italy, Germany, Russia, France, Spain, The Netherlands and Rest of Europe)

Asia-Pacific (India, Japan, China, South Korea, Australia, Indonesia Rest of Asia Pacific)

South America (Colombia, Brazil, Argentina, Rest of South America)

Middle East & Africa (Saudi Arabia, U.A.E., South Africa, Rest of Middle East & Africa)

## Partner Identification

Increase Your Customer Base by 3X using our Partner Identification tool

Uncover strategic collaboration opportunities with DataM vetted partners aligned to your ecosystem.

Identify high potential M&A targets based on synergies, market positioning and growth trajectory.

Prioritize partners by strategic fit rather than general capability.

## Why Choose DataM?

**Data-Driven Insights:** Dive into detailed analyses with granular insights such as pricing, market shares and value chain evaluations, enriched by interviews with industry leaders and disruptors.

**Post-Purchase Support and Expert Analyst Consultations:** As a valued client, gain direct access to our expert analysts for personalized advice and strategic guidance, tailored to your specific needs and challenges.

**White Papers and Case Studies:** Benefit quarterly from our in-depth studies related to your purchased titles, tailored to refine your operational and marketing

strategies for maximum impact.

**Annual Updates on Purchased Reports:** As an existing customer, enjoy the privilege of annual updates to your reports, ensuring you stay abreast of the latest market insights and technological advancements. Terms and conditions apply.

**Specialized Focus on Emerging Markets:** DataM differentiates itself by delivering in-depth, specialized insights specifically for emerging markets, rather than offering generalized geographic overviews. This approach equips our clients with a nuanced understanding and actionable intelligence that are essential for navigating and succeeding in high-growth regions.

**Value of DataM Reports:** Our reports offer specialized insights tailored to the latest trends and specific business inquiries. This personalized approach provides a deeper, strategic perspective, ensuring you receive the precise information necessary to make informed decisions. These insights complement and go beyond what is typically available in generic databases.

## Target Audience 2026

Manufacturers/ Buyers

Industry Investors/Investment Bankers

Research Professionals

Emerging Companies

## Contents

### 1. DEFINITION AND OVERVIEW

- 1.1. Study Objectives
- 1.2. Market Definition
- 1.3. Market Scope
- 1.4. Stakeholder Analysis
- 1.5. Currency Considered
- 1.6. Study Period

### 2. EXECUTIVE SUMMARY

- 2.1. Key Takeaways
- 2.2. Top To Bottom Analysis
- 2.3. Market Share Analysis
- 2.4. Data Points from Key Primary Interviews
- 2.5. Data Points from Key Secondary Databases
- 2.6. Market Snapshot
- 2.7. Geographical Snapshot

### 3. DYNAMICS

#### 3.1. Impacting Factors

##### 3.1.1. Drivers

3.1.1.1. Rising prevalence of psychiatric disorders and substance-induced agitation

3.1.1.2. Increasing emergency department visits related to acute behavioral

disturbances

3.1.1.3. Growing adoption of rapid-acting and novel drug delivery formulations

##### 3.1.2. Restraints

3.1.2.1. Safety concerns and adverse effects associated with antipsychotics and sedatives

3.1.2.2. Stringent regulatory scrutiny and post-marketing safety requirements

##### 3.1.3. Opportunity

3.1.3.1. Development of non-invasive and fast-acting delivery systems (inhaled, intranasal, sublingual)

3.1.3.2. Increasing demand in emerging markets due to improving psychiatric care access

3.1.3.3. Pipeline development targeting agitation in dementia and Alzheimer's

disease

#### 3.1.4. Trends

3.1.4.1. Shift toward atypical antipsychotics with improved safety profiles

3.1.4.2. Increasing preference for rapid-onset formulations in emergency psychiatry

#### 3.1.5. Impact Analysis

## 4. INDUSTRY ANALYSIS

4.1. Porter's Five Force Analysis – Global Bi-level Positive Airway Pressure Devices (BiPAP)

4.2. Geopolitical & Supply Chain Exposure

4.2.1. API Sourcing Concentration for Antipsychotics and Benzodiazepines

4.2.2. Trade Policies, Export Controls, and Psychiatric Drug Supply Risks

4.3. Social & Patient-Centric Factors

4.3.1. Physician Prescribing Behavior in Emergency Psychiatry and Acute Care

4.3.2. Brand Preference vs Generic Substitution Across Antipsychotics and Sedatives

4.3.3. Patient and Caregiver Concerns Regarding Sedation, Safety, and Monitoring

4.3.4. Awareness Gaps in Early Recognition and Management of Acute Agitation

4.4. Economic Factors

4.4.1. Reimbursement and Coverage in Hospital and Emergency Care Settings

4.4.2. Inflationary Pressure on APIs, Sterile Injectables, and CNS Drug Manufacturing

4.4.3. Currency Volatility Impacting Export-Oriented CNS Drug Manufacturers

4.5. Pricing Analysis

4.6. Regulatory Analysis

4.7. Go-To-Market (GTM) Strategy

4.8. Innovation & R&D Trends

4.9. Sustainability and ESG Analysis

4.10. Acute Agitation Treatment Ecosystem Participants

4.11. Buyer Decision Criteria & Adoption Drivers

4.12. DMI Opinion – Strategic Outlook for the Global Bi-level Positive Airway Pressure Devices (BiPAP) Market

## 5. BY PRODUCT

5.1. Introduction

5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

5.1.2. Market Attractiveness Index, By Product

5.2. Devices\*

5.2.1. Introduction

5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

5.2.3. Fixed Pressure BiPAP Devices

5.2.4. Auto-adjusting BiPAP Devices

5.2.5. BiPAP ST (Spontaneous/Timed) Devices

5.2.6. BiPAP AVAPS Devices

5.2.7. Portable / Travel BiPAP Devices

5.2.8. ICU / Critical Care BiPAP Systems

5.2.9. Pediatric / Neonatal BiPAP Devices

5.2.10. Others

5.3. Masks

5.3.1. Full Face Masks

5.3.2. Nasal Masks

5.3.3. Nasal Pillow Masks

5.3.4. Total Face Masks

5.3.5. Pediatric Masks

5.3.6. Others

5.4. Aftermarket Parts and Accessories

5.4.1. Tubing / Breathing Circuits

5.4.2. Humidifiers

5.4.3. Filters

5.4.4. Headgear and Straps

5.4.5. Cushions and Mask Liners

5.4.6. Water Chambers

5.4.7. Batteries and Power Adapters

5.4.8. Carrying Cases

5.4.9. Others

## **6. BY INDICATION**

6.1. Introduction

6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication

6.1.2. Market Attractiveness Index, By Indication

6.2. Obstructive Sleep Apnea\*

6.2.1. Introduction

6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

6.3. Central Sleep Apnea

6.4. Complex Sleep Apnea

6.5. Chronic Obstructive Pulmonary Disease (COPD)

6.6. Acute Respiratory Failure

- 6.7. Chronic Respiratory Failure
- 6.8. Neuromuscular Disorders
- 6.9. Obesity Hypoventilation Syndrome
- 6.10. Pneumonia and Other Respiratory Infections
- 6.11. Post-operative Respiratory Support
- 6.12. Others

## **7. BY TECHNOLOGY**

- 7.1. Introduction
  - 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  - 7.1.2. Market Attractiveness Index, By Technology
- 7.2. Integrated Humidification\*
  - 7.2.1. Introduction
  - 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 7.3. Heated Tubing
- 7.4. Smart Connectivity
- 7.5. Bluetooth-enabled Devices
- 7.6. Wi-Fi-enabled Devices
- 7.7. Cloud-based Monitoring
- 7.8. Telemonitoring Compatible Devices
- 7.9. Noise Reduction Technology
- 7.10. Pressure Relief Technology
- 7.11. Leak Compensation Systems
- 7.12. Touchscreen / Digital Interface
- 7.13. Others

## **8. BY PORTABILITY**

- 8.1. Introduction
  - 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
  - 8.1.2. Market Attractiveness Index, By Portability
- 8.2. Stationary Devices\*
  - 8.2.1. Introduction
  - 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
- 8.3. Portable Devices
- 8.4. Travel-friendly Devices
- 8.5. Others

## **9. BY PATIENT TYPE**

### 9.1. Introduction

9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type

9.1.2. Market Attractiveness Index, By Patient Type

### 9.2. Adult\*

9.2.1. Introduction

9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

### 9.3. Pediatric

### 9.4. Geriatric

## **10. BY END-USER**

### 10.1. Introduction

10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

10.1.2. Market Attractiveness Index, By End-User

### 10.2. Hospitals\*

10.2.1. Introduction

10.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)

### 10.3. Academic / Teaching Hospitals

### 10.4. Sleep Clinics and Sleep Laboratories

### 10.5. Home Healthcare Settings

### 10.6. Ambulatory Surgical Centers

### 10.7. Long-term Care Facilities

### 10.8. Rehabilitation Centers

### 10.9. Others

## **11. BY REGION**

### 11.1. Introduction

11.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region

11.1.2. Market Attractiveness Index, By Region

### 11.2. North America

11.2.1. Introduction

11.2.2. Key Region-Specific Dynamics

11.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product

11.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology

11.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability

- 11.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
- 11.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 11.2.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.2.9.1. US
  - 11.2.9.2. Canada
  - 11.2.9.3. Mexico
- 11.3. Europe
  - 11.3.1. Introduction
  - 11.3.2. Key Region-Specific Dynamics
  - 11.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  - 11.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  - 11.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  - 11.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
  - 11.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  - 11.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  - 11.3.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.3.9.1. Germany
    - 11.3.9.2. UK
    - 11.3.9.3. France
    - 11.3.9.4. Russia
    - 11.3.9.5. Italy
    - 11.3.9.6. Spain
    - 11.3.9.7. Norway
    - 11.3.9.8. Netherlands
    - 11.3.9.9. Sweden
    - 11.3.9.10. Denmark
    - 11.3.9.11. Belgium
    - 11.3.9.12. Switzerland
    - 11.3.9.13. Austria
    - 11.3.9.14. Poland
    - 11.3.9.15. Finland
    - 11.3.9.16. Rest of Europe
- 11.4. Latin America
  - 11.4.1. Introduction
  - 11.4.2. Key Region-Specific Dynamics
  - 11.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  - 11.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  - 11.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  - 11.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability

- 11.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
- 11.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
- 11.4.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
  - 11.4.9.1. Brazil
  - 11.4.9.2. Argentina
  - 11.4.9.3. Rest of Latin America
- 11.5. Asia-Pacific
  - 11.5.1. Introduction
  - 11.5.2. Key Region-Specific Dynamics
  - 11.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  - 11.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  - 11.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  - 11.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
  - 11.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  - 11.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  - 11.5.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
    - 11.5.9.1. China
    - 11.5.9.2. India
    - 11.5.9.3. Japan
    - 11.5.9.4. Australia
    - 11.5.9.5. South Korea
    - 11.5.9.6. New Zealand
    - 11.5.9.7. Indonesia
    - 11.5.9.8. Malaysia
    - 11.5.9.9. Philippines
    - 11.5.9.10. Singapore
    - 11.5.9.11. Thailand
    - 11.5.9.12. Vietnam
    - 11.5.9.13. Rest of Asia-Pacific
- 11.6. Middle East and Africa
  - 11.6.1. Introduction
  - 11.6.2. Key Region-Specific Dynamics
  - 11.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product
  - 11.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Technology
  - 11.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
  - 11.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Portability
  - 11.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By Patient Type
  - 11.6.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Indication
  - 11.6.9. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country

- 11.6.9.1. UAE
- 11.6.9.2. Saudi Arabia
- 11.6.9.3. South Africa
- 11.6.9.4. Israel
- 11.6.9.5. Egypt
- 11.6.9.6. Turkey
- 11.6.9.7. Qatar
- 11.6.9.8. Kuwait
- 11.6.9.9. Oman
- 11.6.9.10. Bahrain
- 11.6.9.11. Rest of Middle East and Africa

## **12. COMPETITIVE LANDSCAPE ANALYSIS**

- 12.1. Competitive Scenario
- 12.2. Market Positioning/Share Analysis
- 12.3. Mergers and Acquisitions Analysis
- 12.4. Partner Identification Analysis
- 12.5. Investment & Funding Landscape
- 12.6. Strategic Alliances & Innovation Pipelines

## **13. COMPANY PROFILES**

- 13.1. Pfizer, Inc.\*
  - 13.1.1. Company Overview
  - 13.1.2. Product Portfolio
  - 13.1.3. Revenue Analysis
  - 13.1.4. Pricing Analysis
  - 13.1.5. SWOT Analysis
  - 13.1.6. Recent Developments
    - 13.1.6.1. Major Deals
    - 13.1.6.2. M&A
    - 13.1.6.3. Collaboration
    - 13.1.6.4. Acquisition
    - 13.1.6.5. Joint Ventures
    - 13.1.6.6. Innovations
  - 13.1.7. Recent News
    - 13.1.7.1. Events
    - 13.1.7.2. Conferences

- 13.1.7.3. Symposiums
- 13.1.7.4. Webinars
- 13.2. Otsuka Pharmaceutical Co., Ltd.
- 13.3. GlaxoSmithKline plc
- 13.4. H. Lundbeck A/S
- 13.5. Johnson & Johnson
- 13.6. Bristol-Myers Squibb Company
- 13.7. BioXcel Therapeutics, Inc.
- 13.8. Impel Pharmaceuticals Inc.
- 13.9. Lee Pharma Limited
- 13.10. Teva Pharmaceutical Industries Ltd.
- 13.11. Amneal Pharmaceuticals LLC
- 13.12. AbbVie Inc.
- 13.13. Aurobindo Pharma Limited
- 13.14. Apotex Inc.
- 13.15. F. Hoffmann-La Roche Ltd.
- 13.16. Hikma Pharmaceuticals PLC
- 13.17. Axsome Therapeutics, Inc.
- 13.18. Alkermes plc
- 13.19. Alexza Pharmaceuticals, Inc. (LIST NOT EXHAUSTIVE )

## **14. GLOBAL BI-LEVEL POSITIVE AIRWAY PRESSURE DEVICES (BIPAP) MARKET – RESEARCH METHODOLOGY**

- 14.1. Research Data
  - 14.1.1. Secondary Data
  - 14.1.2. Primary Data
  - 14.1.3. CAGR Analysis
- 14.2. Market Size Estimation Methodology
  - 14.2.1. Bottom-Up Approach
  - 14.2.2. Top-Down Approach
- 14.3. Market Breakdown & Data Triangulation
- 14.4. Research Assumptions
- 14.5. Limitations

## **15. APPENDIX**

- 15.1. About Us and Services
- 15.2. Contact Us

## I would like to order

Product name: Bi-level Positive Airway Pressure Devices (BiPAP) Market - 2024-2033

Product link: <https://marketpublishers.com/r/B3F6C4A84900EN.html>

Price: US\$ 2,999.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/B3F6C4A84900EN.html>